{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T13:23:37Z","timestamp":1782566617631,"version":"3.54.5"},"reference-count":39,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T00:00:00Z","timestamp":1634428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The use of heated intraperitoneal chemotherapy (HIPEC) in conjunction with cytoreductive surgery has been gaining increasing traction in treating gastric adenocarcinoma with metastasis to the peritoneum in recent years. The addition of laparoscopic HIPEC (LS-HIPEC) to these treatment algorithms has increased the flexibility and adaptability of HIPEC integrating into treatment sequencing, allowing for iterative protocols of LS-HIPEC prior to cytoreduction as neoadjuvant treatment, as well as in the palliation of patients with unresectable disease and uncontrolled ascites. As the use of HIPEC in gastric adenocarcinoma continues to be refined, LS-HIPEC algorithms should continue to be considered and utilized both in curative treatment algorithms as well as in patients in the palliative setting. Given that LS-HIPEC remains a relatively nascent treatment modality, we advocate for its use in the setting of a clinical trial when feasible.<\/jats:p>","DOI":"10.3390\/jcm10204757","type":"journal-article","created":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T23:05:47Z","timestamp":1634511947000},"page":"4757","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Laparoscopic Heated Intraperitoneal Chemotherapy in the Treatment of Carcinomatosis of Gastric Adenocarcinoma Origin"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5022-5505","authenticated-orcid":false,"given":"Michael G.","family":"White","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9915-8355","authenticated-orcid":false,"given":"Brian D.","family":"Badgwell","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000658-198807000-00005","article-title":"Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding","volume":"208","author":"Fujimoto","year":"1988","journal-title":"Ann. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1245\/s10434-017-5838-y","article-title":"Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy","volume":"24","author":"Ikoma","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jso.24087","article-title":"Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases","volume":"113","author":"Shiozaki","year":"2016","journal-title":"J. Surg. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1072-7515(01)00980-2","article-title":"Laparoscopic continuous hyperthermic peritoneal perfusion","volume":"193","author":"Chang","year":"2001","journal-title":"J. Am. Coll. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1245\/s10434-017-6047-4","article-title":"Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma","volume":"24","author":"Badgwell","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11605-015-2995-9","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis","volume":"20","author":"Nadiradze","year":"2016","journal-title":"J. Gastrointest. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: Final results of a phase III randomized clinical trial","volume":"18","author":"Yang","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1245\/s10434-020-08739-5","article-title":"A Phase II Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology","volume":"28","author":"Badgwell","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","article-title":"Peritoneal carcinomatosis from gastric cancer: A multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy","volume":"17","author":"Glehen","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10120-019-00978-0","article-title":"Peritoneal metastasis in gastric cancer: Results from the German database","volume":"23","author":"Rau","year":"2020","journal-title":"Gastric Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.ejso.2018.06.036","article-title":"Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis","volume":"44","author":"Manzanedo","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1002\/cam4.2204","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) in combined treatment of locally advanced and intraperitonealy disseminated gastric cancer: A retrospective cooperative Central-Eastern European study","volume":"8","author":"Yarema","year":"2019","journal-title":"Cancer Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/bjs.11588","article-title":"Treatment of PERItoneal disease in Stomach Cancer with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: PERISCOPE I initial results","volume":"107","author":"Wassenaar","year":"2020","journal-title":"Br. J. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.18.01688","article-title":"Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis","volume":"37","author":"Bonnot","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bonnot, P.E., Lintis, A., Mercier, F., Benzerdjeb, N., Passot, G., Pocard, M., Meunier, B., Bereder, J.M., Abboud, K., and Marchal, F. (2021). Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study). Br. J. Surg.","DOI":"10.1093\/bjs\/znab200"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/jso.23633","article-title":"Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial","volume":"110","author":"Rudloff","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00464-017-5668-9","article-title":"Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer","volume":"32","author":"Badgwell","year":"2018","journal-title":"Surg. Endosc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1245\/s10434-020-08226-x","article-title":"Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology","volume":"27","author":"Ikoma","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1245\/s10434-020-08842-7","article-title":"Factors Associated with Resection and Survival After Laparoscopic HIPEC for Peritoneal Gastric Cancer Metastasis","volume":"27","author":"White","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejso.2007.05.015","article-title":"Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer","volume":"34","author":"Facchiano","year":"2008","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/SLE.0b013e318173a61e","article-title":"Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy","volume":"18","author":"Patriti","year":"2008","journal-title":"Surg. Laparosc. Endosc. Percutan. Tech."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jso.21321","article-title":"Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients","volume":"100","author":"Valle","year":"2009","journal-title":"J. Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12957-020-01956-y","article-title":"Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites","volume":"18","author":"Jiao","year":"2020","journal-title":"World J. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ijsu.2015.09.074","article-title":"Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for refractory malignant ascites in patients unsuitable for cytoreductive surgery","volume":"23","author":"Valle","year":"2015","journal-title":"Int. J. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Raoof, M., Malhotra, G., Kohut, A., O\u2019Leary, M., Frankel, P., Tran, T., Fakih, M., Chao, J., Lim, D., and Woo, Y. (2021). PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial. Ann. Surg. Oncol.","DOI":"10.1245\/s10434-021-10505-0"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20180118","DOI":"10.1515\/pp-2018-0118","article-title":"Study protocol: Phase 1 dose escalating study of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis","volume":"3","author":"Kim","year":"2018","journal-title":"Pleura Peritoneum"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"20180120","DOI":"10.1515\/pp-2018-0120","article-title":"Phase I\/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): Rationale and design","volume":"3","author":"Dumont","year":"2018","journal-title":"Pleura Peritoneum"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"20180116","DOI":"10.1515\/pp-2018-0116","article-title":"PIPAC EstoK 01: Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin (PIPAC C\/D) in gastric peritoneal metastasis: A randomized and multicenter phase II study","volume":"3","author":"Eveno","year":"2018","journal-title":"Pleura Peritoneum"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"De Simone, M., Vaira, M., Argenziano, M., Berchialla, P., Pisacane, A., Cinquegrana, A., Cavalli, R., Borsano, A., and Robella, M. (2020). Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial. Biomedicines, 8.","DOI":"10.3390\/biomedicines8050102"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1758835919846402","DOI":"10.1177\/1758835919846402","article-title":"Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C\/D) in patients with gastric cancer and peritoneal metastasis: A phase II study","volume":"11","author":"Struller","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_31","first-page":"20180113","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with standard of care chemotherapy in primarily untreated chemo naive upper gi-adenocarcinomas with peritoneal seeding\u2014a phase II\/III trial of the AIO\/CAOGI\/ACO","volume":"3","author":"Pabst","year":"2018","journal-title":"Pleura Peritoneum"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.ejso.2015.06.001","article-title":"Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)","volume":"41","author":"Odendahl","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"20180110","DOI":"10.1515\/pp-2018-0110","article-title":"Randomized control trial comparing quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC) and intravenous chemotherapy","volume":"3","author":"Somashekhar","year":"2018","journal-title":"Pleura Peritoneum"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5230\/jgc.2018.18.e37","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Cancer Patients with Peritoneal Metastasis (PM): Results of a Single-Center Experience and Register Study","volume":"18","author":"Gockel","year":"2018","journal-title":"J. Gastric Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1245\/s10434-020-08968-8","article-title":"Laparoscopic HIPEC for Low-Volume Peritoneal Metastasis in Gastric and Gastroesophageal Adenocarcinoma","volume":"27","author":"Blumenthaler","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Yu, P., Ye, Z., Dai, G., Zhang, Y., Huang, L., Du, Y., and Cheng, X. (2020). Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: A prospective cohort study. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07601-x"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Granieri, S., Bonomi, A., Frassini, S., Chierici, A.P., Bruno, F., Paleino, S., Kusamura, S., Germini, A., Facciorusso, A., and Deraco, M. (2021). Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: A meta-analysis of randomized controlled trials. Eur. J. Surg. Oncol.","DOI":"10.1016\/j.ejso.2021.05.016"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Beeharry, M.K., Ni, Z.T., Yang, Z.Y., Zheng, Y.N., Feng, R.H., Liu, W.T., Yan, C., Yao, X.X., Li, C., and Yan, M. (2020). Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): Dragon II trial. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-6701-2"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Koemans, W.J., van der Kaaij, R.T., Boot, H., Buffart, T., Veenhof, A., Hartemink, K.J., Grootscholten, C., Snaebjornsson, P., Retel, V.P., and van Tinteren, H. (2019). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II). BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5640-2"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/20\/4757\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:16:32Z","timestamp":1760166992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/20\/4757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,17]]},"references-count":39,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["jcm10204757"],"URL":"https:\/\/doi.org\/10.3390\/jcm10204757","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,17]]}}}